BridgeBio Pharma (BBIO) Leases: 2020-2025
Historic Leases for BridgeBio Pharma (BBIO) over the last 6 years, with Sep 2025 value amounting to $6.6 million.
- BridgeBio Pharma's Leases rose 1.77% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 1.77%. This contributed to the annual value of $5.8 million for FY2024, which is 28.15% down from last year.
- As of Q3 2025, BridgeBio Pharma's Leases stood at $6.6 million, which was up 5.93% from $6.2 million recorded in Q2 2025.
- BridgeBio Pharma's 5-year Leases high stood at $17.1 million for Q3 2021, and its period low was $5.8 million during Q4 2024.
- Its 3-year average for Leases is $7.7 million, with a median of $7.3 million in 2024.
- In the last 5 years, BridgeBio Pharma's Leases soared by 77.40% in 2021 and then crashed by 32.87% in 2022.
- BridgeBio Pharma's Leases (Quarterly) stood at $15.9 million in 2021, then plummeted by 32.87% to $10.7 million in 2022, then fell by 24.83% to $8.0 million in 2023, then fell by 28.15% to $5.8 million in 2024, then rose by 1.77% to $6.6 million in 2025.
- Its last three reported values are $6.6 million in Q3 2025, $6.2 million for Q2 2025, and $7.2 million during Q1 2025.